Program
SYHX1901
A development code. Also written as “SYHX 1901 tablets”.
Its studies are mostly in Alopecia Areata · Psoriasis · Vitiligo · Drug-Related Side Effects and Adverse Reactions, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 53 open or running | phase 3since Apr 17, 2025 | Apr 27, 2021 | Apr 28, 2027phase 3 · NCT06943950 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
SYHX1901
, phase 3, as of Aug 20, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2021First study: phase 1 study in Healthy SubjectsFirst studyNCT04880512 · 102 enrolled · China
- Mar 3, 2023Phase 2 study in Drug-Related Side Effects and Adverse ReactionsNCT05858047 · 93 enrolled · China
- Jul 2, 2024Phase 2 study in Non-segmental VitiligoNCT06511739 · 144 planned · China
- Aug 18, 2024Phase 2 study in Alopecia AreataNCT06562894 · 156 planned
- Apr 17, 2025Phase 3 study in Moderate to Severe Plaque PsoriasisNCT06943950 · 500 planned
Ahead
- Apr 28, 2027Primary completion: phase 3 study in Moderate to Severe Plaque PsoriasisNCT06943950
- May 31, 2027Primary completion: phase 2 study in Alopecia AreataNCT06562894
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06943950Moderate to Severe Plaque Psoriasis | 3 | Not yet recruiting | Apr 28, 2027 | 500 |
| NCT06562894Alopecia Areata | 2 | Not yet recruiting | May 31, 2027 | 156 |
| NCT06511739Non-segmental Vitiligo · China | 2 | Recruiting | Aug 1, 2025 | 144 |
| NCT05858047Drug-Related Side Effects and Adverse Reactions · China | 2 | Completed | Feb 21, 2024 | 93 |
| NCT04880512Healthy Subjects · China | 1 | UNKNOWN | Aug 20, 2022 | 102 |
How it is read
Names in the registry
- “SYHX1901”, 4 entries
- “SYHX 1901 tablets”, 1 entry
Codes read as this program: SYHX1901.
Conditions, from the studies’ own filings
- Alopecia Areata, 1 study
- Psoriasis, 1 study
- Vitiligo, 1 study
- Drug-Related Side Effects and Adverse Reactions, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.